Navigation Links
Data from Study of Elderly Depressed Patients are Reported for Investigational Compound Lu AA21004 on Symptoms of Major Depressive Disorder (MDD)
Date:5/8/2012

acetylcholine and histamine in specific areas of the brain.

About depression

Depression is a very common, debilitating illness affecting around 121 million people worldwide, according to the World Health Organization (WHO).  Depression was the leading cause of disability and the fourth leading contributor to the global burden of disease in 2000.  According to the National Alliance on Mental Illness (NAMI), depression affects more than 6.5 million of the 35 million Americans aged 65 years or older.

The symptoms of depression can be chronic or recurrent, and impact patients both mentally and physically. Symptoms can include feelings of sadness, anxiety, loss of interest in activities, decreased energy, impaired sleep, impaired concentration or indecisiveness, hopelessness, guilt, persistent physical symptoms such as pain and digestive disorders, and in more severe cases, suicidal thoughts and suicide attempts.

Takeda and Lundbeck alliance

In September 2007, Lundbeck and Takeda formed a strategic alliance for the exclusive co-development and co-commercialization in the United States and Japan of several compounds in Lundbeck's pipeline for the treatment of mood and anxiety disorders. The partnership initially focuses on co-development and co-commercialization of the two most advanced compounds in Lundbeck's pipeline for mood and anxiety disorders, Lu AA21004 and Lu AA24530. If approved, the companies will co-promote the products in the United States and Japan.

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from brain disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company's products are targeted at disorders such as depression and anxiety, psychotic disorders, epileps
'/>"/>

SOURCE H. Lundbeck A/S; Takeda Global Research & Development Center, Inc., U.S.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015 Biosensors ... BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, ... announced financial results for its first fiscal quarter ... Quarter Highlights and Recent Developments: ... in improving its cost structure, driven by lower ...
(Date:8/3/2015)... 3, 2015  Array BioPharma Inc. (NASDAQ: ... quarter and full year of its fiscal year ... Chief Executive Officer of Array, noted, "Binimetinib and encorafenib, ... on track for regulatory submissions in 2016. Additional ... and BRAF-mutant colorectal cancer further validate the value ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 ... its primary and secondary endpoints in a phase III ... (OIC) in adult patients with chronic non-cancer pain. Naldemedine ... (PAMORA). This is the third Phase III trial in ... Study results showed that a 0.2 mg ...
Breaking Medicine Technology:Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
... 2011 Graymark Healthcare Inc. (Nasdaq: ... diagnostic sleep services and an innovator in comprehensive care for ... patients in the fourth quarter of 2010, with a 16% ... shipments, as compared to fourth quarter of 2009. ...
... Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) ... Isis, Development PipelineWhen: , Thursday, January 06, 2011 ... , www.isispharm.comHow: , Live on the Internet.  Simply ... , Kristina LemonidisDirector, Investor Relations(760) 603-2490Amy Blackley, Ph.D.Assistant ...
Cached Medicine Technology:Graymark Healthcare's Sleep Apnea Therapy Program Services Record Number of Patients in Q4 2010 2Graymark Healthcare's Sleep Apnea Therapy Program Services Record Number of Patients in Q4 2010 3
(Date:8/3/2015)... ... , ... The art of preparing and cooking food comes naturally to some. ... age, Nasreen Zereshki was extremely eager to cook Persian cuisine. Now that she is ... Persian Kitchen with the world. , Since Americans tend to be undereducated about Persian ...
(Date:8/3/2015)... Alachua, FL (PRWEB) , ... August 03, 2015 , ... ... peripheral nerve injuries, is scheduled to present at the Wedbush Healthcare Conference on Wednesday, ... , A live webcast and subsequent archived replay of the Company’s presentation may be ...
(Date:8/3/2015)... ... 03, 2015 , ... It’s 25 miles from remote Medicine ... and among its least visited State Parks. The volcanic area beneath Medicine Lake ... at Ahjumawi Lava Springs, part of the Fall River Springs complex. * According ...
(Date:8/3/2015)... ... 03, 2015 , ... A July 9 article from USA Today ... according to the American Dental Association. According to a study by the American Dental ... million in a single year to 2.2 million a year. Dentists and ADA officials ...
(Date:8/3/2015)... ... 03, 2015 , ... From 2006-2017 the number of dental ... market research compiled for the National Association of Dental Laboratories ( NADL ) ... of Labor Statistics. As the number of dental laboratories decreases, dentists will have ...
Breaking Medicine News(10 mins):Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3
... 21 In this unstable economic,environment characterized by ... competition in the,bio/pharma marketplace, retaining your most-valued customers ... posts - from web interactions,and early warning systems ... toward,defining the superior customer experience. , ...
... invited to participate with U.S. Secretary of Health, Michael Leavitt, in ... ... Salt Lake City (Vocus) November 20, 2008 -- MediConnect CEO, ... Health, Michael Leavitt, in the 2008 National Summit on Personalized Health ...
... and Extremely Intuitive to Navigate, Making Shopping for Safety Products Easier ... ... 2008 -- Conney Safety Products is proud to announce that their ... state-of-the-art technology. The new website is faster, more efficient and features ...
... D. and Catherine T. MacArthur Foundation is creating a new ... and opportunities posed by our aging society. In the ... an aging society, one feature of which is that those ... Although the nation will become increasingly gray in subsequent decades, ...
... returned positive results in review of national program , , ... detects 40 percent of cancers and should be carefully ... researchers. , They studied 106,000 people, aged 60 to ... program was in identifying unrecognized disease. Half the people ...
... (NMQF) today applauded the American Medical Association,s recent decision to ... physician and patient advocates to join the Forum in encouraging ... , "Physicians and lawyers -- even politicians -- ... Chief Executive Officer of the Forum. "It,s long past time ...
Cached Medicine News:Health News:Creating Brand Advocates by Delivering the Superior Total Customer Experience 2Health News:MediConnect Participates in 2008 National Health Summit 2Health News:Conney Safety Products, Leader in Safety Equipment and Supplies, Launches New Website 2Health News:New MacArthur network to examine impact of aging society 2Health News:Colorectal Cancer Screens Detect Unrecognized Disease 2Health News:National Minority Quality Forum Applauds AMA's Health Insurer Code of Conduct 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: